Business Context and Reporting Period
This Form 8-K reports on the results of Progyny, Inc.'s 2025 Annual Meeting of Stockholders held on May 22, 2025. The record date for voting was March 28, 2025. A total of 75,720,698 shares, representing 88.39% of all shares entitled to vote, were represented at the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals with the following outcomes:
- Proposal 1 (Election of Directors): All Class III director nominees were elected. Notably, Norman Payson, M.D. received significant withheld votes (24,236,162), while Debra Morris and Elizabeth Bierbower received strong support.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Proposal 3 (Say-on-Pay): Stockholders did not approve the advisory compensation of the Named Executive Officers. Votes against (43,948,036) significantly exceeded votes for (24,399,909).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors. The primary risk highlighted by the voting results is significant shareholder dissatisfaction with executive compensation, as evidenced by the failure of Proposal 3.
Investor Verification Checklist
- Verify the specific reasons for the high number of votes withheld for Director Norman Payson, M.D.
- Review the Company's response to the failed "Say-on-Pay" vote and any planned changes to executive compensation policies.
- Confirm the composition of the Board of Directors following the election of the Class III nominees.